BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2026-07
194 industry Phase 2/3 trial readout(s) and 48 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-07 est. | P2 | AbbVie ABBV | NCT03539536 Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | Non-small Cell Lung Cancer | active not recruiting | 270 |
| 2026-07 est. | P3 | AMAG Pharmaceuticals, Inc. | NCT03893045 A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects | Iron Deficiency Anemia | recruiting | 75 |
| 2026-07 est. | P3 | Infan Industria Quimica Farmaceutica Nacional | NCT04069286 EFFICACY OF ORAL AROEIRA (Schinus Terebinthifolia Raddi) COMPARED TO OMEPRAZOLE IN DYSPEPPSIA | Dyspepsia | not yet recruiting | 474 |
| 2026-07 est. | P1/P2 | PT. Prodia Stem Cell Indonesia | NCT04314687 Stem Cell and Conditioned Medium for Cerebral Palsy | Cerebral Palsy | active not recruiting | 78 |
| 2026-07 est. | P3 | EMS | NCT04670666 Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus | Type 2 Diabetes Mellitus | recruiting | 270 |
| 2026-07 est. | P3 | HUYABIO International, LLC. | NCT04674683 Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma | Unresectable or Metastatic Melanoma; Progressive Brain Metastasis | active not recruiting | 450 |
| 2026-07 est. | P2 | Akeso | NCT04736823 A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC | NSCLC | active not recruiting | 265 |
| 2026-07 est. | P3 | EMS | NCT05028140 Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus | Type II Diabetes | recruiting | 480 |
| 2026-07 est. | P3 | Akebia Therapeutics AKBA | NCT05082571 Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease | Anemia of Chronic Kidney Disease | withdrawn | |
| 2026-07 est. | P3 | Akebia Therapeutics AKBA | NCT05082584 Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating | Anemia of Chronic Kidney Disease | withdrawn | |
| 2026-07 est. | P1/P2 | Prestige Biopharma Limited PBH | NCT05141149 First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer | Pancreatic Cancer | active not recruiting | 80 |
| 2026-07 est. | P2 | Woolsey Pharmaceuticals | NCT05218668 Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL) | Amyotrophic Lateral Sclerosis | active not recruiting | 40 |
| 2026-07 est. | P3 | ZZ Biotech, LLC | NCT05484154 Efficacy and Safety Evaluation of 3K3A-APC in Ischemic Stroke | Ischemic Stroke | withdrawn | |
| 2026-07 est. | P1/P2 | CJ Bioscience, Inc. | NCT05877430 Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | NSCLC; HNSCC; Melanoma; Metastatic Cancer; Advanced Solid Tumor; Advanced Cancer | recruiting | 160 |
| 2026-07 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05943795 A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma | Non-small Cell Lung Adenocarcinoma; Squamous Cell Carcinoma of Lung | active not recruiting | 589 |
| 2026-07 est. | P1/P2 | MBrace Therapeutics | NCT06014658 Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors | Cancer | recruiting | 130 |
| 2026-07 est. | P3 | Italfarmaco | NCT06093672 Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera | Polycythemia Vera | recruiting | 220 |
| 2026-07 est. | P2/P3 | Curadel Surgical Innovations, Inc. | NCT06101745 Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery | Injury of Ureter During Surgery (Disorder) | recruiting | 336 |
| 2026-07 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | NCT06297655 A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A | Hemophilia A | active not recruiting | 60 |
| 2026-07 est. | P1/P2 | Intelligem Therapeutics Australia Pty Ltd. | NCT06310967 A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease | Hyperuricemia; Hypouricemia, Renal | recruiting | 60 |
| 2026-07 est. | P2 | Visirna Therapeutics HK Limited | NCT06322628 A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VSA006 in Chinese NASH Patients | Nash | active not recruiting | 48 |
| 2026-07 est. | P1/P2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT06372626 Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. | Neuroendocrine Carcinoma | unknown | 93 |
| 2026-07 est. | P2 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT06492005 A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer | Triple-Negative Breast Cancer | recruiting | 160 |
| 2026-07 est. | P2 | TLC Biopharmaceuticals, Inc. | NCT06574269 A Study on TLC590 for Managing Postsurgical Pain | Postsurgical Pain Management | recruiting | 120 |
| 2026-07 est. | P2 | AbbVie ABBV | NCT06682988 A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritone | Advanced High-Grade Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancers | recruiting | 110 |
| 2026-07 est. | P3 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT06738251 A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | recruiting | 402 |
| 2026-07 est. | P3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06833307 The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis | Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis | not yet recruiting | 90 |
| 2026-07 est. | P2 | ReproNovo Aps | NCT06993155 A Clinical Trial Evaluating the Efficacy and Safety of Leflutrozole on Testicular Function | Semen Quality | recruiting | 200 |
| 2026-07 est. | P2 | Aphaia Pharma US LLC | NCT07008456 A Study to Investigate the Efficacy and Safety of Two Different Doses of Twice Daily Distal Jejunal-release Dextrose Beads Formulations Combined With a Gel Comp | Obese With Comorbidities; Obese Patients (BMI ≥ 30 kg/m²) | recruiting | 102 |
| 2026-07 est. | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | NCT07044908 TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer | RAS/BRAF Wild Type Colorectal Cancer | recruiting | 72 |
| 2026-07 est. | P1/P2 | Qilu Pharmaceutical Co., Ltd. | NCT07102004 Study of MHB088C for Patients With Advanced Solid Malignant Tumors | Advanced/Metastatic Solid Tumors | recruiting | 515 |
| 2026-07 est. | P2 | Saptalis Pharmaceuticals LLC | NCT07146217 Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection | Bacterial Infections | not yet recruiting | 30 |
| 2026-07 est. | P2 | Marea Therapeutics | NCT07199309 A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol | Hypertriglyceridemia | recruiting | 30 |
| 2026-07 est. | P3 | Staidson (Beijing) Biopharmaceuticals Co., Ltd | NCT07208591 To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome | Acute Respiratory Distress Syndrome (ARDS) | recruiting | 406 |
| 2026-07 est. | P2 | Annexin Pharmaceuticals AB | NCT07259928 Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion | Non-Proliferative Diabetic Retinopathy; Retinal Vein Occlusion | recruiting | 12 |
| 2026-07 est. | P3 | Colgate Palmolive CL | NCT07499115 Efficacy of a Toothpaste in Reducing Plaque, Gingivitis, and Gingival Bleeding | Plaque, Dental; Gingivitis | not yet recruiting | 90 |
| 2026-07-01 | P1/P2 | Erasca, Inc. ERAS | NCT04866134 A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors | Advanced or Metastatic Solid Tumors | completed | 85 |
| 2026-07-01 est. | P1/P2 | Scancell Ltd SCNLD | NCT05329532 Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer | Triple Negative Breast Cancer; Renal Cell Cancer; High Grade Ovarian Serous Adenocarcinoma; Squamous | recruiting | 168 |
| 2026-07-01 | P3 | Amgen AMGN | NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (A | Atopic Dermatitis | terminated | 2621 |
| 2026-07-01 est. | P2 | Sinocelltech Ltd. | NCT06197009 Efficacy and Safety of SCT650C in Participants With Axial Spondyloarthritis | Axial Spondyloarthritis | unknown | 168 |
| 2026-07-01 est. | P2/P3 | Shanghai JMT-Bio Inc. | NCT06319313 Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer | Squamous Cell Non-small Cell Lung Cancer | not yet recruiting | 534 |
| 2026-07-01 | P2 | Eli Lilly and Company LLY | NCT06603571 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight W | Obesity; Overweight | completed | 367 |
| 2026-07-02 | P2/P3 | argenx ARGX | NCT05523167 A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. | Active Idiopathic Inflammatory Myopathy; Myositis; Dermatomyositis; Polymyositis; Immune-Mediated Ne | completed | 265 |
| 2026-07-02 | P2 | ResoTher Pharma | NCT06465303 A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI) | ST Elevation Myocardial Infarction | completed | 66 |
| 2026-07-02 | P2 | Citryll BV | NCT06567470 A Study With CIT-013 in RA Patients | Rheumatoid Arthritis | completed | 96 |
| 2026-07-02 | P3 | Medigen Vaccine Biologics Corp. | NCT07178522 A Study to Evaluate the Immunogenicity and Safety of an EV71 Vaccine (Envacgen®) in Children Aged 6 to <10 Years Compared to Children Aged 2 to <6 Years | Enterovirus 71 Inactivated Vaccine | active not recruiting | 379 |
| 2026-07-02 | P3 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | NCT07790120 A Study to Evaluate the Efficacy and Safety in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hype | Uncontrolled Hypertension; Resistant Hypertension | completed | 256 |
| 2026-07-03 est. | P3 | Boehringer Ingelheim | NCT06370871 Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma | Advanced Soft Tissue Sarcoma; Undifferentiated Pleomorphic Sarcoma (UPS); Myxofibrosarcoma (MFS) | withdrawn | |
| 2026-07-05 | P3 | Colgate Palmolive CL | NCT07398378 Clinical Investigation of Oral Malodor for Max Fresh Toothpaste Containing Zinc Citrate Versus a Commercially Available Regular Fluoride Toothpaste | Oral Malodor | completed | 80 |
| 2026-07-06 | P3 | AstraZeneca AZN | NCT05261399 Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treat | Carcinoma; Non-Small-Cell Lung | active not recruiting | 341 |
| 2026-07-06 | P2 | Eli Lilly and Company LLY | NCT05536804 A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | Overweight; Obesity; Chronic Kidney Disease; Type 2 Diabetes; T2D | completed | 134 |
| 2026-07-06 | P2 | Uniquity One (UNI) | NCT06496607 A Study to Evaluate Solriktug in Adult Participants With Asthma | Asthma | completed | 145 |
| 2026-07-07 | P3 | Grifols Therapeutics LLC GRFS | NCT01983241 Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficie | Pulmonary Emphysema in Alpha-1 PI Deficiency | completed | 345 |
| 2026-07-07 | P3 | UCB Biopharma SRL | NCT04666610 A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Ju | Childhood Absence Epilepsy; Juvenile Absence Epilepsy | completed | 154 |
| 2026-07-07 | P2 | AstraZeneca AZN | NCT06194448 To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations | Lung Cancer | active not recruiting | 76 |
| 2026-07-07 | P3 | CSL Behring | NCT06399289 Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy | Hemophilia B | completed | 23 |
| 2026-07-07 | P2 | Ardelyx ARDX | NCT06553547 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs | Irritable Bowel Syndrome With Constipation (IBS-C) | completed | 72 |
| 2026-07-08 | P1/P2 | Jasper Therapeutics, Inc. JSPR | NCT06162728 Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urt | Chronic Spontaneous Urticaria | completed | 87 |
| 2026-07-08 | P2 | Sirtsei Pharmaceuticals, Inc. | NCT06254612 A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder | Major Depressive Disorder | completed | 497 |
| 2026-07-08 | P3 | Amylyx Pharmaceuticals Inc. AMLX | NCT06747468 Avexitide for Treatment of Post-Bariatric Hypoglycemia | Post Bariatric Hypoglycemia | active not recruiting | 75 |
| 2026-07-09 | P3 | Bristol-Myers Squibb BMY | NCT04039607 A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma | completed | 732 |
| 2026-07-09 | P3 | Regeneron Pharmaceuticals REGN | NCT06548100 A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystroph | Generalized Lipodystrophy | completed | 9 |
| 2026-07-09 est. | P2 | Hansoh BioMedical R&D Company | NCT06926582 A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis | Psoriasis | not yet recruiting | 305 |
| 2026-07-09 | P2 | Shanghai Minwei Biotechnology Co., Ltd | NCT07791524 Phase 2 Study of MWN109 Tablet in Participants With Overweight or Obesity | Overweight , Obesity | completed | 255 |
| 2026-07-10 | P3 | BioNTech SE BNTX | NCT05543616 A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children | SARS-CoV-2 Virus; Severe Acute Respiratory Syndrome Coronavirus 2; COVID-19 | completed | 4338 |
| 2026-07-10 | P3 | AstraZeneca AZN | NCT06564844 A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tu | Non-small Cell Lung Cancer | active not recruiting | 25 |
| 2026-07-10 | P3 | Ultragenyx Pharmaceutical Inc RARE | NCT06617429 Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS) | Angelman Syndrome | terminated | 129 |
| 2026-07-10 est. | P2 | Shanghai Henlius Biotech | NCT07269782 A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC | Non Small Cell Lung Cancer | recruiting | 60 |
| 2026-07-10 est. | P1/P2 | Shanxi Kangbao Biological Product Co., Ltd. | NCT07433387 Exploratory Study of LP-98 for Injection in ART-Naive HIV-Infected Individuals | HIV | recruiting | 30 |
| 2026-07-13 | P1/P2 | GlaxoSmithKline | NCT06405230 Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positro | Lung Cancer, Non-Small Cell | terminated | 2 |
| 2026-07-13 | P3 | EyePoint Pharmaceuticals, Inc. EYPT | NCT06668064 A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 | Wet Age Related Macular Degeneration; wAMD | active not recruiting | 400 |
| 2026-07-13 | P2 | Aperta Biosciences, LLC | NCT06720896 A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Pati | Blepharitis | completed | 66 |
| 2026-07-13 | P2 | HK inno.N Corporation | NCT07073677 A Study to Evaluate the Efficacy and Safety of IN-115314 Ointment in Mild to Moderate Atopic Dermatitis Adult Patients | Mild to Moderate Atopic Dermatitis | recruiting | 162 |
| 2026-07-14 | P3 | Chiesi Farmaceutici S.p.A. | NCT05164341 Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL | Partial Lipodystrophy | completed | 69 |
| 2026-07-14 | P3 | AstraZeneca AZN | NCT05583227 Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis | Eosinophilic Esophagitis | active not recruiting | 368 |
| 2026-07-14 | P1/P2 | Ossium Health, Inc. | NCT05589896 A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malign | Acute Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Acute Biphenotypic Leukemia; A | active not recruiting | 12 |
| 2026-07-14 | P3 | AbbVie ABBV | NCT05995340 ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars | Atrophic Acne Scars | completed | 157 |
| 2026-07-14 | P2 | Takeda TAK | NCT06254950 A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | active not recruiting | 213 |
| 2026-07-14 | P2/P3 | EyeBiotech Ltd. | NCT06571045 A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME | Diabetic Macular Edema (DME) | active not recruiting | 984 |
| 2026-07-14 | P2 | GlaxoSmithKline | NCT06748053 A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma | Asthma | active not recruiting | 307 |
| 2026-07-14 | P3 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT06827431 The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression | Major Depressive Disorder (MDD) | completed | 786 |
| 2026-07-14 | P3 | Bayer | NCT07023341 A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic Cardiomyopathy | active not recruiting | 36 |
| 2026-07-14 | P2 | Atom Therapeutics Co., Ltd | NCT07145229 Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare | Acute Gouty Arthritis; Gout Flare; Gout Flares; Acute Gout Flare | completed | 479 |
| 2026-07-14 | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT07446309 Safety and Efficacy of HRS-9190 Compared to Cisatracurium for Continuous Intravenous Infusion in Adults | Neuromuscular Blockade | completed | 67 |
| 2026-07-15 | P3 | Jazz Pharmaceuticals JAZZ | NCT05152147 A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal | Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma | active not recruiting | 920 |
| 2026-07-15 est. | P3 | Alexion Pharmaceuticals, Inc. | NCT05644561 Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis | Generalized Myasthenia Gravis; gMG | active not recruiting | 12 |
| 2026-07-15 | P3 | AbbVie ABBV | NCT05814627 Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Se | Rheumatoid Arthritis | completed | 487 |
| 2026-07-15 | P1/P2 | EMD Serono Research & Development Institute, Inc. | NCT05882734 Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) | Non-Small Cell Lung Cancer | completed | 61 |
| 2026-07-15 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT06057610 A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer | HER2-PositiveRecurrent or Metastatic Breast Cancer | active not recruiting | 868 |
| 2026-07-15 est. | P2 | Can-Fite BioPharma CANF | NCT06387342 Namodenoson Treatment of Advanced Pancreatic Cancer | Pancreatic Adenocarcinoma; Pancreatic Cancer | recruiting | 20 |
| 2026-07-15 est. | P2 | Jemincare | NCT06509334 Trial of JYB1904 in Chronic Spontaneous Urticaria. | Chronic Spontaneous Urticaria | recruiting | 135 |
| 2026-07-15 est. | P2 | Immunis, Inc. | NCT06600581 Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness | Muscle Performance; Sarcopenic Obesity | active not recruiting | 55 |
| 2026-07-15 | P3 | Definium Therapeutics US, Inc. DFTX | NCT06741228 A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage) | Generalized Anxiety Disorder | active not recruiting | 214 |
| 2026-07-15 est. | P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT07116824 HB1801 Combined Treatment of HER2-positive Breast Cancer | HER2-positive Breast Cancer | not yet recruiting | 80 |
| 2026-07-15 | P2 | Citryll BV | NCT07147959 PET-Based Imaging of Radiolabeled CIT-013 | RA | completed | 7 |
| 2026-07-15 | P3 | Sinovac Biotech Co., Ltd SVA | NCT07416110 Phase IIIb Clinical Trial to Evaluate Lot-to-lot Consistency of Sinovac Rabies Vaccine | Rabies (Healthy Volunteers) | active not recruiting | 912 |
| 2026-07-15 | P2 | Clear Scientific, Inc. | NCT07459166 A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade | Fentanyl Overdose; Fentanyl Poisoning | completed | 16 |
| 2026-07-15 est. | P3 | Sinovac (Dalian) Vaccine Technology Co., Ltd. | NCT07475000 Second Dose of Varicella Vaccine in Healthy Children | Varicella (Chickenpox); Varicella Immunisation | recruiting | 300 |
| 2026-07-15 | P2 | Arctic Therapeutics | NCT07774364 Safety and Efficacy of Topical AT-004 1% in Participants With Acne Vulgaris (AV) | Acne Vulgaris on the Face | completed | 63 |
| 2026-07-16 | P3 | Novartis Pharmaceuticals NVS | NCT04023552 Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD | Cardiovascular Disease and Lipoprotein(a) | completed | 8323 |
| 2026-07-16 | P2 | Immunovant Sciences GmbH IMVT | NCT07188844 An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Chronic Inflammatory Demyelinating Polyneuropathy | terminated | 26 |
| 2026-07-17 | P2 | Connect Biopharm LLC CNTB | NCT06940141 Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma) | Asthma Acute | completed | 160 |
| 2026-07-18 | P3 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT06649344 A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 | Type 2 Diabetes | completed | 884 |
| 2026-07-18 est. | P2 | Keymed Biosciences Co.Ltd | NCT06947980 Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis | recruiting | 200 |
| 2026-07-19 est. | P3 | AbbVie ABBV | NCT05316220 A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis | Ulcerative Colitis (UC) | withdrawn | |
| 2026-07-20 | P2 | Immunovant Sciences GmbH IMVT | NCT05581199 To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP | Chronic Inflammatory Demyelinating Polyneuropathy | terminated | 94 |
| 2026-07-20 | P2 | Vertex Pharmaceuticals Incorporated VERX | NCT06794996 Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities | Proteinuric Kidney Disease | completed | 42 |
| 2026-07-20 | P3 | GlaxoSmithKline | NCT07220109 A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Resp | Respiratory Syncytial Virus Infections | active not recruiting | 750 |
| 2026-07-21 | P2 | Takeda TAK | NCT02616302 A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old | Gastroesophageal Reflux Disease (GERD) | completed | 71 |
| 2026-07-21 | P3 | Bristol-Myers Squibb BMY | NCT04036435 Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis | Psoriasis | completed | 1466 |
| 2026-07-21 | P3 | Novartis Pharmaceuticals NVS | NCT05147220 Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1) | Relapsing Multiple Sclerosis | active not recruiting | 1000 |
| 2026-07-21 | P3 | PTC Therapeutics PTC | NCT05166161 A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria | Phenylketonuria | completed | 247 |
| 2026-07-21 | P3 | Eli Lilly and Company LLY | NCT06649045 A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight | OSA; Overweight or Obesity | completed | 712 |
| 2026-07-21 | P3 | Pharvaris Netherlands B.V. PHVS | NCT06669754 Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE | Hereditary Angioedema (HAE) | completed | 85 |
| 2026-07-21 | P2 | Jasper Therapeutics, Inc. JSPR | NCT06736262 A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria | Urticaria Chronic | terminated | 67 |
| 2026-07-21 | P2 | SPARK Biopharma SPKLF | NCT06747923 SB17170 Phase 2 Trial in IPF Patients | IPF; Idiopathic Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis (IPF) | completed | 32 |
| 2026-07-21 | P1/P2 | Regeneron Pharmaceuticals REGN | NCT07218770 A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants | Active Noninfectious Uveitis Affecting the Posterior Segment | terminated | 1 |
| 2026-07-22 | P3 | Hoffmann-La Roche | NCT04543617 A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Follo | Esophageal Squamous Cell Carcinoma | completed | 760 |
| 2026-07-22 | P3 | UCB Biopharma SRL | NCT04901195 A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa | completed | 658 |
| 2026-07-22 | P3 | Novartis Pharmaceuticals NVS | NCT05156281 Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) | Relapsing Multiple Sclerosis | active not recruiting | 1007 |
| 2026-07-22 | P3 | RDC Clinical Pty Ltd | NCT05232279 Effect of Testofen on Erectile Function in an Adult Male Population | Erectile Dysfunction | completed | 64 |
| 2026-07-22 | P2 | Aptabio Therapeutics, Inc. | NCT05758896 Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI | Contrast Induced Acute Kidney Injury | completed | 218 |
| 2026-07-22 | P2 | Gilead Sciences GILD | NCT06101329 Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102) | Pre-Exposure Prophylaxis of HIV Infection | active not recruiting | 253 |
| 2026-07-22 | P1/P2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT06233292 A Study of ZG005 in Patients With Advanced Solid Tumors | Solid Tumors | completed | 125 |
| 2026-07-22 | P3 | Takeda TAK | NCT06439342 A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections | Cytomegalovirus (CMV) | completed | 20 |
| 2026-07-22 | P2 | Beijing Inno Medicine Co., Ltd. | NCT06700720 YN001-004 in Patients With Coronary Atherosclerosis in Australia | Coronary Artery Disease; Coronary Atherosclerotic Disease | terminated | 3 |
| 2026-07-22 | P2 | Hoffmann-La Roche | NCT06863961 A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | active not recruiting | 162 |
| 2026-07-22 | P2/P3 | Qlaris Bio, Inc. | NCT07354516 Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension | OAG - Open-Angle Glaucoma; OHT - Ocular Hypertension | completed | 64 |
| 2026-07-23 | P2 | Pfizer PFE | NCT03307980 Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B | Hemophilia B | terminated | 21 |
| 2026-07-23 | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT04626518 Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) | Carcinoma, Renal Cell | completed | 263 |
| 2026-07-23 | P1/P2 | Binhui Biopharmaceutical Co., Ltd. | NCT05235074 OH2 Oncolytic Viral Therapy in Central Nervous System Tumors | Central Nervous System Tumors | completed | 40 |
| 2026-07-23 | P3 | Amgen AMGN | NCT06104124 A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity | Sjogren's Syndrome | completed | 651 |
| 2026-07-23 | P3 | Avidity Biosciences, Inc. | NCT06411288 Global Study of Del-desiran for the Treatment of DM1 | DM1; Myotonic Dystrophy; Myotonic Dystrophy 1; Myotonia; Myotonic Dystrophy Type 1 (DM1); Dystrophy | completed | 159 |
| 2026-07-23 est. | P2/P3 | Shanghai Vitalgen BioPharma Co., Ltd. | NCT06432140 A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Severe AADC Deficiency | Aromatic L-amino Acid Decarboxylase Deficiency | active not recruiting | 13 |
| 2026-07-23 | P2 | Evommune, Inc. EVMN | NCT07150845 Phase 2b Study of EVO756 in Adults With Atopic Dermatitis | Atopic Dermatitis | completed | 121 |
| 2026-07-23 | P2 | Verdiva Bio Dev Limited | NCT07281937 A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Obesity; Overweight | completed | 206 |
| 2026-07-24 | P3 | ModernaTX, Inc. | NCT06067230 A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | Respiratory Syncytial Virus | completed | 1153 |
| 2026-07-24 | P3 | BioNTech SE BNTX | NCT07222384 A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe C | COVID-19; SARS-COV-2 Infection | completed | 344 |
| 2026-07-27 est. | P3 | AstraZeneca AZN | NCT04884360 D9319C00001- 1L OC Mono Global RCT | Ovarian Cancer | active not recruiting | 366 |
| 2026-07-27 | P1/P2 | Immunis, Inc. | NCT05211986 Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis. | Muscle Atrophy | completed | 13 |
| 2026-07-27 | P2 | Gilead Sciences GILD | NCT06101342 Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103) | Pre-Exposure Prophylaxis of HIV Infection | active not recruiting | 181 |
| 2026-07-27 | P2 | AbbVie ABBV | NCT06236880 A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD | Major Depressive Disorder | completed | 126 |
| 2026-07-27 | P2 | Beijing Continent Pharmaceutical Co, Ltd. | NCT07417553 A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis | Chronic Hepatitis B-related Liver Fibrosis | completed | 67 |
| 2026-07-28 | P3 | ReGenTree, LLC | NCT05555589 Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 | Neurotrophic Keratopathy | completed | 70 |
| 2026-07-28 est. | P1/P2 | Lantern Pharma Inc. LTRN | NCT05933265 Study of LP-184 in Patients With Advanced Solid Tumors | Advanced Solid Tumor; Metastatic Solid Tumor; GBM; TNBC - Triple-Negative Breast Cancer; NSCLC; Panc | active not recruiting | 64 |
| 2026-07-28 | P3 | Beijing Continent Pharmaceutical Co, Ltd. | NCT07343778 A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis | Chronic Hepatitis B With Hepatic Fibrosis | completed | 337 |
| 2026-07-29 | P3 | Mirum Pharmaceuticals, Inc. MIRM | NCT06553768 Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) | Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) | active not recruiting | 90 |
| 2026-07-29 | P2 | Processa Pharmaceuticals PCSA | NCT06568692 A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer | Breast Cancer; TNBC - Triple-Negative Breast Cancer; HER2-negative Breast Cancer | terminated | 20 |
| 2026-07-29 | P1/P2 | Incyte Corporation INCY | NCT06873789 A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors | Solid Tumors; Advanced Solid Tumors; Metastatic Solid Tumors | terminated | 9 |
| 2026-07-29 est. | P2 | Lanzhou Institute of Biological Products Co., Ltd | NCT07445815 A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody | Rabies (Healthy Volunteers) | not yet recruiting | 200 |
| 2026-07-30 | P3 | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | NCT04724369 Open-Label Study of 18F-mFBG for Imaging Neuroblastoma | Neuroblastoma | completed | 43 |
| 2026-07-30 | P3 | Biogen BIIB | NCT04729907 A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who T | Muscular Atrophy, Spinal | completed | 115 |
| 2026-07-30 est. | P3 | Pfizer PFE | NCT05261139 EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Ho | COVID-19 | recruiting | 160 |
| 2026-07-30 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05320692 A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma | Hepatocellular Carcinoma | active not recruiting | 423 |
| 2026-07-30 est. | P1/P2 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | NCT05744427 Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors | Advanced Solid Tumor | active not recruiting | 725 |
| 2026-07-30 est. | P2 | Shanghai Institute Of Biological Products | NCT06194656 Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma | Head and Neck Squamous Cell Carcinoma | recruiting | 81 |
| 2026-07-30 est. | P2 | Levee Medical, Inc. | NCT06275945 Feasibility Study of A VoRo UrologIc ScaffolD (ARID) | Stress Urinary Incontinence; Radical Prostatectomy | active not recruiting | 40 |
| 2026-07-30 | P2 | atai Therapeutics, Inc. | NCT06524830 A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) | Treatment Resistant Depression | completed | 142 |
| 2026-07-30 | P2 | Sanofi SNY | NCT06637631 A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease. | Crohn's Disease | terminated | 105 |
| 2026-07-30 | P3 | Gan & Lee Pharmaceuticals. | NCT06777238 A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Di | Type 2 Diabetes Mellitus (T2DM) | completed | 274 |
| 2026-07-30 est. | P3 | CSPC Megalith Biopharmaceutical Co.,Ltd. | NCT06927986 Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC(SYNSTAR01) | EGFR-mutated Locally Advanced or Metastatic NSCLC | recruiting | 380 |
| 2026-07-30 | P2 | Connect Biopharm LLC CNTB | NCT06940154 Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD) | COPD Acute Exacerbation | completed | 159 |
| 2026-07-30 | P2 | Altimmune, Inc. ALT | NCT06987513 RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight | Alcohol Use Disorder (AUD) | completed | 100 |
| 2026-07-30 est. | P1/P2 | NSC-Therapeutics | NCT06995573 A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease | Alzheimer Disease | recruiting | 90 |
| 2026-07-30 est. | P2 | InventisBio Co., Ltd | NCT07035041 A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis | UC - Ulcerative Colitis; Moderately to Severely Active Ulcerative Colitis | active not recruiting | 120 |
| 2026-07-30 | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT07314060 A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis | Generalized Pustular Psoriasis | terminated | 36 |
| 2026-07-30 est. | P2 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | NCT07579936 A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens | Postmenopausal Women With Osteoporosis | recruiting | 200 |
| 2026-07-31 est. | P2 | OHB Neonatology Ltd. | NCT03253263 A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants | Bronchopulmonary Dysplasia; Chronic Lung Disease of Prematurity; Intraventricular Hemorrhage; Retino | active not recruiting | 295 |
| 2026-07-31 est. | P2 | Xynomic Pharmaceuticals, Inc. | NCT03936153 Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | Diffuse Large B-cell Lymphoma (DLBCL) | recruiting | 170 |
| 2026-07-31 est. | P2 | Frantz Viral Therapeutics, LLC | NCT04098744 Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3) | CIN 2/3; HPV Infection; Pre-Cancerous Dysplasia; Cervical Dysplasia; HPV Related Disease | recruiting | 78 |
| 2026-07-31 | P3 | UCB Biopharma SRL | NCT04225871 Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis | Generalized Myasthenia Gravis | completed | 200 |
| 2026-07-31 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT04639180 A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence Afte | Hepatocellular Carcinoma (HCC) | active not recruiting | 687 |
| 2026-07-31 est. | P1/P2 | Idience Co., Ltd. | NCT04725994 Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer | Gastric Cancer | active not recruiting | 87 |
| 2026-07-31 | P2 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT05445908 SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer | Triple-negative Breast Cancer and HR+/HER2- BC | completed | 184 |
| 2026-07-31 est. | P3 | Kringle Pharma, Inc. | NCT05627648 Phase 3 Study of KP-100LI in Subjects With Vocal Fold Scar | Vocal Fold Scar | active not recruiting | 62 |
| 2026-07-31 | P2 | Syntara | NCT05904717 Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder | REM Sleep Behavior Disorder | completed | 40 |
| 2026-07-31 est. | P2 | Hansoh BioMedical R&D Company | NCT06112704 HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors | Advanced Solid Tumor | recruiting | 220 |
| 2026-07-31 | P1/P2 | Pfizer PFE | NCT06137742 A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | completed | 97 |
| 2026-07-31 | P2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | NCT06297226 Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | recruiting | 230 |
| 2026-07-31 est. | P1/P2 | YourChoice Therapeutics, Inc. | NCT06542237 Open Label, Dose Escalation, Repeat Dose Study Evaluating YCT-529 in Healthy Males | Male Contraception | recruiting | 88 |
| 2026-07-31 | P3 | Hoffmann-La Roche | NCT06624059 A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC) | Non-Small Cell Lung Cancer | completed | 11 |
| 2026-07-31 est. | P1/P2 | NEC Bio B.V | NCT06631079 Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors | Solid Tumor | active not recruiting | 20 |
| 2026-07-31 | P1/P2 | SK Bioscience Co., Ltd. | NCT06680128 A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adul | Japanese Encephalitis Virus Disease | completed | 161 |
| 2026-07-31 est. | P3 | SK Plasma Co., Ltd. | NCT06738901 An Open-label Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of SKP-0141 for the Treatment and Prophylaxis in Severe Hemophilia a P | Hemophilia A, Severe | not yet recruiting | 55 |
| 2026-07-31 est. | P2 | Glaceum | NCT06845553 A Study to Assess the Efficacy and Safety of Vutiglabridin in Knee Osteoarthritis Patients | Knee Osteoarthritis (Knee OA) | recruiting | 60 |
| 2026-07-31 | P2 | Ono Pharmaceutical Co., Ltd. | NCT06881836 A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease | Alzheimer Disease | completed | 260 |
| 2026-07-31 est. | P1/P2 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | NCT07090954 A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma | Multiple Myeloma | not yet recruiting | 32 |
| 2026-07-31 est. | P1/P2 | Shanghai JMT-Bio Inc. | NCT07140809 a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia | Hypertriglyceridemia | recruiting | 48 |
| 2026-07-31 est. | P2 | Clarent Biopharma, Inc. | NCT07204639 Safety and Efficacy of CBP-0276 to Improve Severity and Quality of Life on Moderate to Severe Psoriasis in Subjects | Psoriasis | recruiting | 100 |
| 2026-07-31 est. | P3 | MAXVAX Biotechnology Limited Liability Company | NCT07272434 Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell) | Respiratory Syncytial Virus (RSV) | recruiting | 25000 |
| 2026-07-31 est. | P2 | Neurodawn Pharmaceutical Co., Ltd. | NCT07275762 Y-4 to Treat the Postherpetic Neuralgia | Postherpetic Neuralgia; Y-4; Pregabalin | recruiting | 160 |
| 2026-07-31 est. | P2 | Oui Therapeutics, Inc. | NCT07316088 Determining the Potential for Efficacy of OTX-601 in Reducing PTSD Symptoms | PTSD; Post Traumatic Stress Disorder | active not recruiting | 40 |
| 2026-07-31 est. | P2 | Linno Pharmaceuticals, Inc. | NCT07387302 SLN12140 in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China | Paroxysmal Nocturnal Hemoglobinuria (PNH) | not yet recruiting | 10 |
| 2026-07-31 est. | P1/P2 | Juvena Therapeutics | NCT07397468 To studyJUV-161 Administered to Healthy Volunteers Undergoing Unilateral Lower Limb Immobilization (ULLI) | Healthy Volunteers | recruiting | 36 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.